Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Continually confident about Eli Lilly because of the enormous success of its weight loss and diabetes drugs, CNBC's Jim Cramer said the company's new Alzheimer's treatment has the potential to further boost business. On Monday, a panel of advisors to the Food and Drug Administration unanimously recommended the drug, currently known as donanemab.

Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug

Eli Lilly and Company has gained approval on yet another prospective blockbuster drug, Donanemab, the second FDA-approved Alzheimer's treatment on the market. It is too soon to know what kind of impact Lilly's Donanemab will have on future earnings, but I predict it will be fairly positive. Eli Lilly has proven its commitment to product depth and innovation, one of the many reasons it's the largest holding at my firm.

Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval

BofA Securities analyst Geoff Meacham reiterated the Buy rating on Eli Lilly And Company LLY, with a price forecast of $1,000.

Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst

Eli Lilly's stock has seen significant gains due to the success of its GLP-1 franchise and the potential of donanemab for Alzheimer's disease. The FDA's Advisory Committee endorsed donanemab for Alzheimer's treatment, but concerns remain post-approval requirements. Though competition in the Alzheimer's market is limited, sales projections for anti-amyloid antibodies may be overhyped.

Eli Lilly: The Road To Approval Of Donanemab Is Open

24/7 Wall Street Insights Unlike the declining stocks of some of its pharmaceutical rivals, Eli Lilly has continually beat analysts' forecasts and prospered accordingly.

Here's Why Eli Lilly Will Likely Announce a Stock Split

Eli Lilly stock reversed premarket gains at the open Tuesday after an FDA panel endorsed its Alzheimer's treatment, donanemab.

Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win

Eli Lilly (NYSE: LLY ) stock is continuing a recent rally over the last year as a Food and Drug Administration (FDA) panel signs off on its Alzheimer's drug. The FDA panel voted unanimously in favor of Eli Lilly's donanemab in a recent meeting.

Eli Lilly Stock Hits New 52-Week High as FDA Panel Recommends Alzheimer's Drug

Eli Lilly (LLY) Alzheimer's disease drug, donanemab, receives Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) recommendation.

Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod

Shares of Eli Lilly And Co (NYSE:LLY) are enjoying a 2.3% surge this morning, last seen trading near $885.10 on the back of news that the Food and Drug Administration (FDA) panel unanimously approved the pharmaceutical company's Alzheimer's drug, donanemab.

FDA Nudge Sends Pharma Stock to Fresh Record Highs

Applied Therapeutics Inc

Insmed

Transmedics Group Inc

As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 4 Health Care Stocks That May Keep You Up At Night This Month

Lilly's current product lineup includes multiple growth drivers, including Mounjaro and Zepbound. The company's pipeline also features promising candidates, with two currently awaiting regulatory approvals.

Eli Lilly Hits an All-Time High: Is the Soaring Pharma Stock Still a Buy?

Eli Lilly (LLY) shares gained more than 2% in extended trading on Monday after a panel of independent advisors to the Food and Drug Administration (FDA) unanimously recommended the pharmaceutical giant's Alzheimer's drug donanemab, increasing the likelihood of its approval in the U.S. later this year.

Eli Lilly Stock Gains After FDA Advisors Recommend Alzheimer's Drug Donanemab

Regeneron Pharmaceuticals

Biotech stocks to check out in the stock market now.

2 Biotech Stocks For Your June 2024 Watchlist

Eli Lilly and Company (NYSE:LLY ) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024 4:00 PM ET Company Participants Patrik Jonsson - Executive Vice President, President of Lilly Diabetes and Obesity and Lilly USA Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay, let's get underway here for the Lilly session. One of the most and highly anticipated and we're so appreciative of the entire Lilly team that's here.

Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference

Alzheimer's could eventually be a “very big category” for Eli Lilly & Co (NYSE: LLY), says Dr Scott Gottlieb. He's the former commission of the U.S. Food & Drug Administration.

Alzheimer's could be a ‘very big category' for Eli Lilly: former FDA commissioner

A Food and Drug Administration advisory panel unanimously voted Monday to recommend Eli Lilly's Alzheimer's drug donanemab for approval, according to multiple outlets, sending the pharmaceutical company's shares up modestly in after-hours trading and making the treatment's final approval more likely.

FDA Panel Unanimously Recommends Eli Lilly's Alzheimer's Drug

Apple

Considering how many Apple products there are out there in the world at this time, a high number of them will soon be accessing A.I. from an Apple device.

Apple Joins A.I. Race; Lilly Thumbs-Up on Alzheimer's Drug

Data from Eli Lilly's late stage trial on experimental obesity pill orforglipron is expected in April 2025, a top Eli Lilly executive said on Monday.

Eli Lilly exec expects obesity pill data in April 2025

Eli Lilly & Co.'s experimental Alzheimer's drug donanemab on Monday moved a step closer to U.S. regulatory approval as it won support from an independent panel of advisers to the Food and Drug Administration.

Eli Lilly's Alzheimer's drug gets backing from FDA advisers

A top Eli Lilly executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro.

Eli Lilly exec says seeing out of pocket payments for obesity drug in US

A panel of independent advisors to the FDA recommended Eli Lilly's Alzheimer's drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year. If approved, Eli Lilly's drug would become the second Alzheimer's drug of its kind to enter the U.S. market after another treatment called Leqembi from Biogen and Eisai.

FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval

C3.ai

AMC Entertainment

General Electric

Reddit Inc

Tesla

Admittedly, bailing on over-hyped stocks to sell can seem like a regretful move in the near-term. Flying in the face of the Wall Street adage “let your winners run,” it's common to feel regretful when you sell said hot stocks, only to see them get even hotter and head higher.

7 Over-Hyped Stocks to Sell Before They Plunge: June Edition

Eli Lilly stock inched ahead Monday as a panel of advisors to the FDA gathered to discuss its experimental Alzheimer's treatment, donanemab.

Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug

An independent advisory panel to the U.S. Food and Drug Administration will vote later on Monday on the safety and effectiveness of Eli Lilly's experimental Alzheimer's drug donanemab.

US FDA advisers to review Eli Lilly Alzheimer's drug

A panel of experts advising the Food and Drug Administration could on Monday recommend Eli Lilly's experimental Alzheimer's drug donanemab for FDA approval, a closely watched decision that could pave the way for the drug to become the second of its kind authorized in the U.S..

News for Eli Lilly Stock (LLY)